Neu-001, a first-in-class neural plasticity modulator designed to restore visual function in patients with amblyopia, has officially entered Phase 2a clinical development. This multicenter clinical study is designed primarily to evaluate safety, tolerability, and dose response across multiple dosing regimens in approximately 30 amblyopia patients.
A key advantage of this Phase 2a study is that Neu-001 is being evaluated directly in the intended patient population. While the primary objective remains safety assessment, the inclusion of amblyopia patients provides an important opportunity to generate early clinical signals of efficacy, including improvements in visual acuity and functional vision.
Unlike conventional approaches that rely primarily on childhood treatment windows, Neu-001 is based on the concept of reactivating and enhancing neural plasticity within the visual system. By modulating the underlying neural circuits responsible for visual processing, Neu-001 aims to reopen a period of plasticity and enable recovery of visual function beyond the traditional developmental window.
The Phase 2a multicenter study represents an important translational milestone, providing the first systematic clinical evaluation of Neu-001’s ability to safely engage neural plasticity mechanisms in adults and older children with amblyopia. Positive safety findings together with early efficacy signals could establish clinical proof-of-concept and support subsequent pivotal development.
With approximately 30 patients enrolled across multiple centers, this study is designed to provide critical information on dosing, safety, biological activity, and the potential therapeutic impact of Neu-001 as a novel disease-modifying treatment for amblyopia.
“Neu-001 challenges the long-held belief that the visual system has limited capacity for recovery beyond childhood.”
Professor Jufang He